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Abstract
Prostate cancer is the most common malignancy among men in the US. Though considerable improvement in the
diagnosis of prostate cancer has been achieved in the past decade, predicting disease outcome remains a major
clinical challenge. Recent expression profiling studies in prostate cancer suggest microRNAs (miRNAs) may serve
as potential biomarkers for prostate cancer risk and disease progression. miRNAs comprise a large family of about
22-nucleotide-long non-protein coding RNAs, regulate gene expression post-transcriptionally and participate in
the regulation of numerous cellular processes. In this review, we discuss the current status of miRNA in studies
evaluating the disease progression of prostate cancer. The discussion highlights key findings from previous studies,
which reported the role of miRNAs in risk and progression of prostate cancer, providing an understanding of the
influence of miRNA on prostate cancer. Our review indicates that somewhat consistent results exist between these
studies and reports on several prostate cancer related miRNAs. Present promising candidates are miR-1, −21, 106b,
141, −145, −205, −221, and −375, which are the most frequently studied and seem to be the most promising for
diagnosis and prognosis for prostate cancer. Nevertheless, the findings from previous studies suggest miRNAs may
play an important role in the risk and progression of prostate cancer as promising biomarkers.
Background
Prostate cancer (PCa) is the most common malignancy
among men in the US. In 2016, there were approxi-
mately 180,890 new cases and 26,120 PCa related deaths
[1]. Over the past two decades, PCa detection with
serum prostate specific antigen (PSA/KLK3) has led to a
significant increase in the detection of low-grade PCa
(Gleason < 6), a disease that has been shown to pose
little risk of either metastatic spread or death. Active
surveillance has thus evolved as a recommended man-
agement strategy for men with low grade disease. On
the other hand, in 10 to 15% of cases, the cancer is
aggressive and advances beyond the prostate, sometimes
turning lethal, characterized by recurrence and early
metastasis through the bloodstream and lymphatic
system. Moreover, distant disease is associated with a
low 5-year survival rate of 28% (2014–2015 ACS Cancer
Treatment and Survivorship Facts and Figures). It
should also be noted that racial differences may influ-
ence the diagnosis and also the progression and PCa
treatment [2].
The most important clinical challenge is to distinguish
men who have a potentially lethal form of PCa from
those with an indolent disease [3]. Given the significant
morbidity associated with treatment interventions, active
surveillance could help identify men with aggressive
disease who would benefit from intensive treatment
compared to those in which conservative measures
would suffice. Currently, the stratification of PCa patients
is guided by the PSA kinetics, clinical stage, and the grade
of tumor (Gleason score). Although these parameters are
still clinically useful, they have limitations in detecting
cases, predicting disease outcomes and guiding clinical
management decisions. For example, the sensitivity of
PSA with standard cut-off of 4 ng/mL is only 20.5% while
the specificity is 93.6% [4]. Thus new biomarkers are
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urgently needed to improve existing diagnostic, prognostic
and treatment management plans. Results from numerous
reports suggest a critical role of microRNAs (miRNAs) in
PCa progression (reviewed in [5]). These studies reveal ex-
pression of miRNAs are dysregulated in prostate tumor
and indicated miRNAs may serve as promising PCa risk
stratification biomarkers [5].
miRNAs comprise a large family of ~22-nucleotide-
long non-protein coding RNAs that regulate gene ex-
pression post-transcriptionally by both destabilizing
mRNA transcripts and repressing their translation. Since
the discovery of the first miRNA (lin-4) in 1993 [6],
many other miRNAs have been identified [5, 7]. Report-
edly, miRNAs normally regulate cellular processes such
as development and differentiation in multicellular
organisms [8, 9]. Subsequent studies found that expres-
sion of miRNAs are significantly associated with various
human cancers, including prostate cancer. For example,
miR-143, miR-145, and miR-375 were identified as
biomarkers with a high-level sensitivity and specificity in
PCa detection [10], albeit unequivocally [5].
Most miRNAs bind at the 3′ untranslated regions
(3′ UTR), 5′ UTR and coding mRNA regions, which
leads to mRNA degradation or translational inhibition
[11–13]. miRNAs regulate the activity of more than
60% of all human gene products [9, 14, 15]. Biological
functional studies suggest miRNAs are involved in the
regulation a plethora of cellular processes, including
those essential to tumorigenesis [14]. Each miRNA
may regulate hundreds of genes with varying specific-
ities through base pairing to mRNAs [16]. Moreover,
a certain gene may serve as a targeted by multiple
miRNAs via different binding sites [17, 18]. Therefore,
a miRNA can play a role in multiple biological cell
signaling pathways by regulating the expressions and
functions of their target genes [19]. Currently, there
are over 1,800 human miRNAs identified. Many of
them are expressed in a tissue-specific manner and
changes in the expression of certain miRNAs are
associated with various cancers including PCa (miRBase
Release 21, www.mirbase.org) [14].
In this review, we will provide overview information
on the current status of miRNA studies in PCa. The
discussion will highlight key findings from human
studies, examine the expression of miRNA in prostate
tumor tissues with a view to understand the influence
of miRNAs on prostate carcinogenesis or possibly the
modulation of the clinical course of the disease. We
will also review studies comparing the expression of
miRNAs in different biological states of PCa via
tumor tissue and biological fluid relative to controls.
The review will conclude with a discussion of the thera-
peutic potential of miRNAs in PCa and on future
directions of miRNA research in PCa.
miRNA and prostate cancer
miRNAs affect gene expression significantly and their
dysregulation may cause tumorigenesis and its progres-
sion. The first report of miRNA’s role in human cancer
came from a study that characterized chromosome
13q14 in chronic lymphocytic leukemia (CLL) [20].
Since the first report of aberrant miRNA expression in
CLL, the dysregulation of a number of miRNAs is
closely associated with the development and progression
of various cancers. Furthermore, about 50% of miRNA
sequences are located in cancer-related regions (includ-
ing fragile sites, breakpoint regions, viral integration sites
and regions frequently linked with loss of heterozygosity
or amplification) in the human genome, suggesting a
role of miRNAs in cancer [21]. Moreover, recent studies
indicated the dysregulation of miRNA profiles in PCa
based on high-throughput methodologies (i.e., micro-
arrays, RNA-Seq, proteomic arrays).
Further, miRNA expression profiles may help to distin-
guish between normal and tumor tissues [22–28].
miRNA profiles appear to have a better accuracy to
differentiate between tumor and normal tissues when
compared to mRNA profiling [29]. Expression profiles of
miRNAs often correspond with clinic-pathological
parameters and predict patient outcome or response to
treatment [22, 30, 31]. These observations underscore
the potential of miRNAs as new diagnostic or prognostic
biomarkers. Additionally, the oncogenic or tumor-
suppressive functions of miRNAs [24, 32] suggested
that miRNAs may be new candidates for cancer drug
treatment. Beyond that, miRNAs has also been shown
to be more stable than the mRNA and are therefore
more suitable to be measured in formalin-fixed
paraffin-embedded (FFPE) samples [33, 34]. The stability
of miRNAs also makes miRNAs better candidates for
blood-based markers [35, 36].
Dysregulation of miRNA in cancer could be caused by
several genomic aberrations. These genomic anomalies
may include, chromosomal modification, such as
translocation, change of transcriptional factors and
aberrant expression, epigenetic alterations, and changes
in miRNA processing [22]. Several studies reveal miR-
155 is induced at the transcriptional level by transform-
ing growth factor β (TGFB1)/Smad, nuclear factor-κB
(NFKB1) and activator protein-1 (AP1) family transcrip-
tion factors (JUN/JUNB/JUND/FOS/FOSB) through
direct interaction with the miR-155 promoter [37–39].
miRNAs as oncogenes and tumor suppressors
miRNAs are divided into two types, oncogenes or tumor
suppressors based upon whether their targets. Several
miRNAs have been characterized as oncogenes and
tumor suppressors in PCa. miRNAs inhibit the expres-
sion of tumor suppressor genes via their up-regulation
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in tumor cells, and are commonly termed oncogenic
miRNAs or onco-miRs. The oncogenic miRNAs in PCa
may enhance proliferative function by down-regulation
of cell-cycle dependent kinase inhibitors p21 and p27
[40–42], as well as members of the E2F family of tran-
scription factors [40, 43]. For example, miR-17-92 clus-
ter contains six miRNAs (miR-17, −18a, −19a, −19b-1,
−20a, and -92a-1) that are over-expressed in PCa [44],
particularly miR-20a is over-expressed in prostate tumor
tissues [45]. miR-20a decreases apoptosis in PCa PC-3
cells through repression of E2F2 and E2F3 and inhibition
of miR-20a by antisense oligonucleotide, inducing the
cell death [43]. Others PCa-associated onco-miRs, miR-
1, −21, −106b, −125b, −221 and −222 are known.
The expression of miR-1, also considered an onco-
miRNA, is inversely related to the WDR6, XPO6 and
SMARCA4 expression. However, miR-1 expression cor-
relates positively with TWF1 transcription (PTK9) in
PCa cells, suggesting that microRNAs binding may lead
to mRNA cellular accumulation and sequestration of the
inhibited mRNA. miR-1 also inhibit expression of
exporter-6 and protein tyrosine kinase 9 (also referred to
as A6/twinfilin) in PCa cells [40]. Chang et al. [46]
showed that decreased miR-1 levels was modulate by the
activation of EGFR, leading to invasiveness and the
involvement of TWIST1 in facilitating metastasis bone
in PCa cell lines. These results indicated that EGFR
functions as a transcription factor, repressing miR-1,
which has an onco-suppressive role [46]. Kojima et al.
[47] showed a down-regulation of miR-1, miR-15a, miR-
16-1, and miR-133a in PCa tissues, and these negative
regulations contributed to the proliferation, migration
and invasion in PC3 and DU145 cells. miR-1 and
miR-133a may functioned as tumor suppressors that
regulate PNP, an oncogenic gene in Pca [47]. Ambs et al.
[40] and Martens-Uzunova et al. [48] observed down-
regulation in PCa tissues and linked to PCa progression,
castration-resistant disease, and metastasis. Therefore, miR-1
was also suggested at candidate prognostic biomarker
for Pca [46, 47, 49–53].
The miR-21 is overexpressed and plays an important
role in PCa tumorigenesis, stimulating invasion and
metastasis [45, 54–58], and induced invasion and motil-
ity of prostate tumor cells [59]. Ribas et al. [57] demon-
strated androgen-induced Androgen Receptor binding to
the miR-21 promoter that showed a direct transcrip-
tional regulation, even after castration. Their results
demonstrated that miR-21 contribute to PCa androgen
receptor-driven proliferation and was overexpressed in
LNCaP and LAPC-4 cells and in human tumors, but not
correlate with stage, grade, or PSA [57]. The coordinated
action of miR-21 and androgen receptor signaling, sup-
presses TGFBR2 levels through binding to its 3'UTR,
enhancing androgen receptor signaling, thereby exerting
its oncogenic effects on prostate tumors, through inhib-
ition the suppressor activity of the tumor by TGFβ path-
way [59]. The miR-21 may be implicated in the
resistance to apoptosis, in motility and invasion in PCa
cells [60]. miR-21 is able to downregulate Cyclin
dependent kinase inhibitors expression by targeting the
coding region of the gene, being able to attenuate the
p57Kip2 action, which is inhibit the cell cycle [59]. An
overexpressed miR-21 can lead to a decrease in the
levels of RECK (Reversion-inducing cysteine-rich protein
with Kazal motifs, a key inhibitor of several metalopro-
teinases) as well, and consequently cause an increase in
the PCa promotion and progression [58].
miR-106b which targets the p21 (CDKN1A) and
E2F1, displays an anti-apoptotic role in PCa cells by
inhibiting caspase activation. Thus miR-106 sup-
pressed E2F1 and p21/WAF1 protein expression [40].
Ambs et al. [40] and Szczyrba et al. [61] observed
over-expression of miR-106b in gene expression pro-
filing of prostate tumors. miR-106b appears to be a
PCa oncogene, and was suggested as a candidate
prognostic marker for PCa [62–64].
miR-125b is usually was over-expressed in androgen-
independent PCa cells, but was downregulated in
androgen-dependent LNCaP cells. Ectopic expression of
miR-125b in LNCaP cells stimulates growth as a conse-
quence of downregulation of its major target BAK1, a
pro-apoptotic gene belonging to the Bcl-2 family [65,
66]. The miR-145 binds to the 3'UTR of MYO6 gene
and regulated negatively, resulting in a decrease in
myosin VI (involved in cancer-related cell migration),
and β-actin in LNCaP cell line [61].
Poliseno et al. [62] has shown that miR-25, miR-93,
and miR-106b are up-regulated in PCa and are inversely
correlated with PTEN (phosphatase and tensin homolog
deleted on chromosome 10, is a tumor suppressor that
antagonizes signaling via the phosphatidylinositol-3-
kinase-Akt pathway) abundance in prostate cancer. The
authors also observed that miR-22 transformed MEFs
(mouse embryonic fibroblasts) when combined with c-
MYC (a regulatory gene encoding a transcription factor),
as well as the miR-106b-25 cluster when combined with
c-MYC or when combined with MCM7 (mini-chromosome
maintenance protein 7). The expression of MCM7
correlated with tumor progression [62].
Hudson et al. [49] have observed that miR-32, miR-
106b-25, and miR-375 are up-regulated in primary
tumor tissues and miR-106b-25 showed an additional in-
creased in metastatic lesions especially in bones. On the
other hand, miR-101 was down-regulated in tumors and
metastases. The caspase-7, a novel candidate target of
miR-106b-25, and its inhibition may be important in
anti-apoptotic and oncogenic functions, promote cell
cycle progression and hyper-proliferation, and miR-
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106b-25 can also alter the cell adhesion properties in
PCa. miR-106b-25 negatively regulates Fas-activated
kinase involved in apoptosis. The authors hypothesized
that the combined inhibition of pro-apoptotic E2F1, Bim
(apoptosis regulator), Fas-activated kinase (serine/threo-
nine transferase kinase/transferase), caspase-7 and
PTEN provides miR-106b-25 expressing in cancer cells.
In addition, the down-regulation of cell death-inducing
integrin-beta 8, which is a target of miR-106b-25, and
miR-93, can still support independent growth anchorage
[49]. Liang et al. [64] have observed that REST (RE-1
Silencing Transcription Factor) expression decreases
with overexpression of miR-93 and miR-106b-25
induced in LNCaP and PC3 cells hypoxia, and ele-
vated expression of pro-neural Phox2a, as well the
ASH-1 transcription factors and TH and ChgA NE
markers. On the other hand, under conditions of
hypoxia, excessive expression of miR-93 led to the
destruction of REST [64].
The miR-200c also is upregulation, and it’s targets with
ZEB1 and ZEB2, that are transcription factors, that also
are able to negatively regulate the miR-200c expression,
thus increasing E-cadherin expression [61]. miR-205 has
an onco-suppressive function by inhibiting the transition
from epithelial to mesenchymal tissue, cell migration,
and invasion in the human prostate [48]. Knockdown
of miR-221 and miR-222, which are upregulated in
the androgen-independent PCa cancer cell line,
reduced the clonogenecity and tumorigenicity of
androgen-independent PC-3 cells [41, 42]. Ectopic
expression of miR-221 and miR-222 enhanced the
colony forming potential and in vivo growth of
androgen-dependent LNCaP cells by inducing a G1-S
shift in the cell cycle [41].
In contrast to onco-miRs, tumor suppressor miRNAs
were down-regulated in tumor cells to permit tumor
progression. For example, the miR-15a/16-1 cluster
located on chromosome 13q14 was frequently deleted in
about 50% of PCa tumors [67]. Decreased activity of
these two miRNAs resulted in hyperplasia of the
prostate in mice and increased expression through intra-
tumoral delivery resulted in the regression of PCa xeno-
grafts [67, 68]. miR-15a–miR-16-1 cluster controlled cell
survival, proliferation and invasion by suppressing cyclin
D1 (CCND1) and WNT3A [67]. Similarly, miR-101
expression in PCa was decreased during progression of
the disease mainly due to the loss of one or both of its
genomic loci. Moreover, miR-101 inhibited the expres-
sion and function of EZH2, a member of the polycomb
protein group [69].
The tumor-suppressive role of miRNAs in PCa has
generally been ascribed to their ability to interfere with
cell migration, invasion and pro-apoptotic functions.
Ectopic expression of miR-126* significantly reduced the
translation of prostein (SLC45A3), which is a prostate-
specific protein involved in PCa motility and invasive-
ness. Presumably, miR-126 binds to the 3′ UTR of pros-
tein mRNA, resulted in reduced invasiveness of LNCaP
cells [70]. Similarly, ectopic miR-34a expression induced
cell cycle arrest and senescence, inhibited cell growth,
and attenuated resistance to the chemotherapeutic agent
camptothecin. miR-126 increased chemotherapy sensi-
tivity by inducing apoptosis through suppression of the
deacetylase sirtuin (SIRT1) and cyclin dependent kinase
6 (CDK6) and aggressive cellular behavior [71, 72].
Moreover, miR-146a reduced cell proliferation, inva-
sion and metastasis of PC-3 cells to human bone mar-
row endothelial cell monolayers through the suppression
of the Rho-associated protein kinase ROCK1 [73]. Other
tumor suppressor-associated miRNAs evaluated in PCa
cell models included miR-23b, miR-145, and miR-205.
Ectopic expression of miR-23b, and miR-145 in LNCaP
cells significantly reduced proliferation [74–77]. Simi-
larly, ectopic expression of miR-205 in PCa cells resulted
in reduction of cell locomotion and invasion and down-
regulation of several oncogenes involved in PCa progres-
sion [78].
Although functional studies might define certain miR-
NAs as onco-miRNAs or tumor suppressor miRNAs,
their expression in prostate tumors might not correlate
with these classifications. For instance, miR-125b, miR-
221, miR-222, miR-373 and miR-520c as onco-miRs in
experimental models [41, 42, 65, 66]; however, these
miRs were down-regulated in prostate tumor tissue
relative to normal prostate tissue [76, 79–81]. miR-373
and miR-520c play a critical role in PCa by inhibiting
expression of CD44 RNA [82]. Other miRNAs also
defied their given classification as either a tumor sup-
pressor or oncogenic miRNAs. Previous functional stud-
ies demonstrated a dual role for miRs-133b and −375 in
different PCa cell lines [83–85].
Normally, miR-133b is downregulated as a tumor sup-
pressor miR and miR-375 is upregulated as an oncomiR
in PCa tumor tissue relative to normal tissue. However,
forced expression of miR-133b increased proliferation in
androgen-dependent cells (LNCaP, 22Rv1) [84] while
miR-375 decreased proliferation and invasion of
androgen-independent PC-3 cells [85]. Thus functional
studies performed in experimental models might not
perfectly recapitulate clinical disease [86]. In the same
way, miR-373 was 1.5 times more prevalent in benign
glandular and benign stromal cells, than in the same
tissues from PCa patients, as well as miR-520c showed
reduced in primary tumors and metastases. Never the
less, miR-373 and miR-520c act as pro-invasive agents,
mediated by binding with CD44 3'UTR [82].
In summary, miRNAs have an important role in
human cancer. More than 50% of miRNA genes are
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located in cancer-associated regions in the human gen-
ome and the expressions of miRNAs are dysregulated in
various human cancers, including PCa. Certain miRNAs
are upregulated in cancer (onco-miRs), while others are
downregulated (tumor suppressors). However, expres-
sion profiles and functional studies of miRNAs in PCa
cell lines do not always correlate with expression in
prostate tumor tissue.
miRNAs in prostate cancer
Numerous biomarkers have been proposed as promis-
ing predictors for risk and/or progression of PCa.
However, most biomarkers could not clearly demon-
strate their independent clinical potential and, there-
fore, these biomarkers fail to enhance accuracy of
current nomograms. Since the first discovery of miR-
NAs [6] in 1993, many studies have investigated
whether dysregulation of miRNA expression in PCa
may correlate with the risk and progression of this
disease. These studies reported a number of differen-
tially expressed miRNAs in biological samples from
patients with PCa. Tables 1 and 2 summarize results
from studies of miRNA expression in PCa.
Diagnosis/progression of prostate cancer based on tissue
MicroRNA profiling in PCa tissues shows different ex-
pression patterns as compared with normal tissues.
These unique miRNA expression profiling may provide
tools for better prediction of diagnosis and progression
of PCa. These data also assist to determine treatment
strategies of PCa.
Porkka et al. [87] reported that differential expression
of 51 miRNAs between BPH and prostate tumor tissues
based on data from oligonucleotide array hybridization.
Eight of these miRNAs were upregulated, while 22 were
down-regulated in tumor tissues as compared with ones
in BPH tissues. The authors observed an expression of
several miRNAs, Let-7f, miR-19b, −184, and −198, were
associated with advanced disease. Ambs et al. [40] evalu-
ated mRNAs profiles detected in 60 LCM prostate
tumors and 16 non-tumor prostate tissues using
genome-wide expression assays. Expression of some
miRNAs was significantly different comparing prostate
tumors and non-tumor samples (miR-32, −133a-1, −490,
−494, −520 h) as well as patients with organ-confined
PCa vs. extra prostatic disease extension (miR-101-1/2,
−200a, and -200b). These data suggested that miRNA
dysregulation was related to development and progres-
sion of PCa. Further, the mRNA and miRNA analyses
revealed influence the expression of cancer related genes
by miRNAs in PCa cells. For example, the miR-106b-25
cluster maps to intron 13 of MCM7, which was signifi-
cantly up-regulated in prostate tumors [40].
Ozen et al. [79] analyzed the expression of 480 human
miRNAs between 10 benign peripheral zone tissues and
16 prostate tumors using microarrays and observed and
validated down-regulation of several miRNAs including
let-7c, miR-125b, and miR-145 in localized prostate
tumor samples compared to benign peripheral zone
tissue, and demonstrated miR-145 expression has a
heterogeneous pattern in PCa tissue [79]. Mercateli et
al. [42] showed overexpression of miR-221 is suffi-
cient to strongly induce growth of LNCaP xenografts
in mice. The tumor growth advantage in miR-221 ex-
pressing was significantly higher than mice in the ref-
erent group (p = 0.01). The average volume fold
increase of miR-221 expressing tumors was higher
than control tumors (p = 0.025) [42].
With high-throughput liquid phase hybridization (mir-
MASA) reactions and 114 miRNA probes, Tong et al.
[76] observed downregulation of miR-221 and other
miRNAs (miR-23b, −100, −145, and −222) in malignant
prostate tissue (n = 40). They developed the 48 miRNA
signature (including miR-135b and miR-194) that pre-
dicted biochemical recurrence after prostatectomy.
Further evidence was provided for the growth modula-
tory roles of miRNAs by showing reduced ectopic ex-
pression of miR-23b, −145, −221 and −222 in LNCaP
cell [76]. Khan et al. [88] analyzed over 1,000 proteins
with multidimensional liquid phase peptide fractionation
followed by tandem mass spectrometry, using 15 tissues
samples, 5 of the prostate tumor, 5 of adjacent benign
tissue and 5 of distant metastatic tissues. The study
revealed the involvement of miR-128-a/b in regulating
progression of PCa, where the miR-128 levels were
elevated in lines of BPH prostatic epithelial cells, when
compared to invasive PCa cells. The findings were
validated in an independent set of 15 clinical specimens.
Furthermore, transient overexpression of miR-128 in
PCa cell lines attenuated cellular invasion, which suggest
miR-128 as an important negative regulator of cellular
invasiveness in vitro [88].
Prueitt et al. [80] showed a role of miRNAs in PCa
progression by demonstrating a higher expression of 19
miRNAs (particularly miR-224) and downregulation of
34 miRNAs (particularly metallothioneins and proteins
with mitochondrial localization and involvement in cell
metabolism) in patients with progression than those
with a locally confined disease [80]. However, Kristensen
et al. [89] reported epigenetic downregulation of miR-
224 and miR-452 (which are located in an intron of the
GABRE) was a significant independent adverse predictor
for time to BCR after radical prostatectomy in two large
PCa patient cohorts (n = 293 and 198, respectively) [89].
Wang et al. [90] analyzed about 273 miRNAs using cell
lines from 62 PCa patients with aggressive phenotype
(Gleason score ≥ 8) and 63 PCa patients with nonaggressive
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Table 1 Summary of miRNA expression studies on samples from prostate cancer patients
Author year (reference) Tissue/serum Outcome miRNA identified
Risk/Diagnostic
Ozen, 2008 [79] Tissue Risk/Diagnostic Let-7b-g, 26a-b, 29a-c, 30a-e, 99a-b, 125a-b
Gandellini, 2009 [78] Tissue Risk/Diagnostic miR-205
Mahn 2011 [118] Tissue/Serum Diagnostic let7i, 16, 26a, 195
Wach, 2012 [10] Tissue Diagnostic miR-143, 145, 375
Avgeris, 2013 [101] Tissue Diagnostic miR-145
Srivastava, 2013 [105] Tissue/Urine Diagnostic miR-205, 221, 99b
Tsuchiyama, 2013 [106] Tissue Diagnostic miR-182-5p
Guzel 2015 [107] Tissue Diagnostic miR-361-3p, 133b, 221, 203
Roberts, 2015 [128] Tissue/Serum Diagnostic miR-200b, 200c, 375
Kristensen 2016 [112] Tissue Diagnostic Up: miR-375, 663b, 615-3p, 425-5p, 663a, 182-5p, 183-5p.
Down: miR-205-5p, 221-3p, 222-3p, 376c-3p, 136-5p, 455-3p,
455-5p, −154-5p
Mitchell, 2008 [35] Serum Diagnostic miR-141
Lodes, 2009 [137] Serum Diagnostic miR-16, 92a, 103, 107
Moltzahn, 2011 [99] Serum Diagnostic miR-26b, 223, 874, 1274a
Yaman Agaoglu, 2011 [54] Plasma Diagnostic miR-21, 141, 221
Selth, 2012 [114] Serum Diagnostic miR-141, 298, 346, 375
Chen 2012 [119] Plasma Diagnostic let7c, let7e, 30c, 622, 1285
Cheng, 2013 [120] Serum Diagnostic miR-210
Haldrup, 2014 [113] Serum Diagnostic miR-141, 375
Westermann, 2014 [121] Serum Diagnostic miR-141
Kachakova, 2015 [122] Plasma Diagnostic let-7c, 375
Haj-Ahmad, 2014 [126] Urine Diagnostic miR-182-5, 484
Korzeniewski, 2014 [127] Urine Diagnostic miR-483-5p, 1275, 1290
Risk/Progression
Porkka, 2007 [87] Tissue Risk/Progression Let-7a-d, Let-7f, 19b, 145, 184, 198, 202, 210,
Ambs, 2008 [40] Tissue Risk/Progression miR-1, 32, 101, 106b, 182, 200a, 200b, 494, 520 h
Mercatelli, 2008 [42] Tissue Progression miR-221, 222
Prueitt, 2008 [80] Tissue Progression miR-2, 10, 125b, 224
Tong, 2009 [76] Tissue Risk/Progression miR-23b, 100, 135b, 145, 194, 221, 222
Wang, 2009 [90] Tissue Progression miR-9*, 16, 221, 222, 331-3p, 145, 551a
Szczyrba, 2010 [61] Tissue Progression miR-143
Shaefer, 2010 [81] Tissue Risk/Progression miR-96, 205
Pesta, 2010 [93] Tissue Progression miR-20a
Khan, 2010 [88] Tissue Progression miR-128
Spahn, 2010 [91] Tissue Progression miR-221
Hagman, 2010 [92] Tissue Risk/Progression miR-34c
Brase, 2011 [115] Tissue/Serum Progression miR-141, 375
Barnabas, 2011 [103] Tissue Progression miR-151
Leite, 2011 [138] Tissue Progression let7c, miR-100, miR-145, miR-191
Martens-Uzunova, 2012 [48] Tissue Progression miR-1, 133a, 133b, 143, 143*, 145, 145*, 204, 221, 222
Li, 2012 [55] Tissue Progression miR-21
Tsuchiyama, 2013 [106] Tissue Progression miR-182-5p
Amankwah, 2013 [102] Tissue Progression miR-21
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phenotype (Gleason grade ≤ 5) and identified a significant
association with PCa grade in 7 miRNAs included miR–16,
−9*, −145, 222, −221, −331-3p, and -551a, especially the
miR-145 and miR-331-3p, showed significantly down-
regulated in aggressive PCa [90].
Schaefer et al. [81] analyzed tumor tissue and normal
adjacent tissue from two groups of 76 and 79 men with
untreated PCa. This study demonstrated miR-130b with
a significantly different expression between normal and
tumor tissues. miRs-125b, −205 and −222 were signifi-
cantly related to tumor stage while miRs-31, −96 and
−205 showed a significant correlations with Gleason
score. When the combination of six miRNAs (miR-96,
−149, −181b, −182, −205 and −375) was used, the AUC
was significant (0.88) in discriminating normal and
tumor tissue [81]. Spahn et al. [91] analyzed samples
from BPH, primary PCa of a high risk group and
corresponding metastatic tissues by microarray analysis.
A PCa specific miRNA expression signature was
generated based on the differential expression of 66 (48
downregulated and 18 upregulated) miRNAs between
tumor and BPH tissues (p < 0.01). They observed a
progressive downregulation of miR-221 in aggressive
and metastatic PCa. Downregulation of miR-221 was
also associated with Gleason score and clinical recur-
rence [91].
Hagman et al. [92] found the relative expression of
miR-34c was significantly lower in the PCa samples
compared to the BPH samples (p = 0.0005) and de-
creased with higher grade. The miR-34c level in patients
with metastasis was found to be significantly lower than
patients without metastasis (p = 0.02). The expression of
miR-34c distinguishes aggressive from non-aggressive
PCa (p = 0.012) and was inversely correlated with PSA
level. Although there was no significant correlation
between miR-34c expression levels and treatment/
response to treatment, the expression of miR-34c was
significantly correlated with survival [92].
Table 1 Summary of miRNA expression studies on samples from prostate cancer patients (Continued)
He, 2013 [134] Tissue Progression miR-19a, miR-374b
Kristensen, 2014 [89] Tissue Progression miR-224, 452
Wang, 2014 [124] Tissue/Serum Progression miR-19, miR-345, miR-519c-5p
Dip, 2015 [139] Tissue Progression Let-7c
Zhang, 2011 [100] Serum Progression miR-21
Yaman Agaoglu, 2011 [54] Plasma Progression miR-21, miR-221
Shen, 2012 [56] Plasma Progression miR-20a, miR-21, miR-145, miR-221
Watahiki, 2013 [123] Plasma Progression miR-21, −126, −141, −151-3p, −152, −200c,-375, −423-3p
Nguyen, 2013 [116] Serum Progression miR-141, miR-375, miR-378, miR-409-3p
Diagnostic/Progression
Hao, 2011 [95] Tissue Diagnostic/Progression miR-21
Mihelich, 2011 [98] Tissue Diagnostic/Progression miR-96, miR-182, miR-183
Bryant 2012 [117] Serum/Urine Diagnostic/Progression miR-181a-2, miR-625, miR-107, miR-574-3p, miR-20a,
miR-23a, miR-624
Mavridis, 2013 [109] Tissue Diagnostic/Progression miR-224
Larne, 2013 [108] Tissue Diagnostic/Progression miR-96-5p, miR-183-5p, miR-145-5p, miR-221-5p
Walter, 2013 [110] Tissue Diagnostic/Progression Up: miR-122, miR-335, miR-184, miR-193, miR-34, miR-138,
Down: miR-373, −9, −198, −144 -215, −96, −222, −148,
−92, −27, −125, −126, −27
Casanova-Salas, 2014 [111] Tissue/Serum Diagnostic/Progression miR-187 and miR-182
Mihelich, 2015 [125] Serum Diagnostic/Progression let-7a, −24, −26b, −30c, −93, −100, −103, −106a, −107,
−130b, −146a, −223, −451, −874,
Kristensen, 2016 [112] Tissue Diagnostic/Progression miR185-5p, miR-221-3p, miR-326
Treatment response
He, 2013 [134] Tissue Treatment Response miR-23b, miR-220, miR-221, miR-222, and miR-205
Lichner, 2013 [135] Tissue Treatment Response miR-152
Gonzales, 2011 [133] Plasma Treatment Response miR-141
Cheng, 2013 [120] Serum Treatment Response miR-210
Someya, 2015 [136] Blood Treatment Response miR-99a
Luu et al. BMC Urology  (2017) 17:18 Page 7 of 18
Table 2 Summary of miRNA expression studies on prostate tumor/serum samples
miRNA investigated Expression Tissue Reference
let-7a-2,let-7i,16-1,17-5p,20a,21,24-1,25,27a,29a,29b-2,30c,32, 34a,92-2,93-1,
95,101-1, 106a, 124a-1,126a-1,135-2,146,149, 181b-1,184,187,191,196-1 197,
199a-1, 214,128a, 195,198, 199a-1,199a-2,203,206,214,218-2,223,
up tumor Volina, 2006 [45]
202,210,296,320,370,373*,498,503 up tumor Porkka, 2007 [87]
let-7i,25,26a-1/2,31,32,34b,92-1/2,93,99b,106b,125a,181a-1/2,182,
188,194-1/2,196a/2,200c, 370, 375,425,449
up tumor Ambs, 2008 [40]
221,222 up tumor Mercatelli, 2008 [42]
16,19b,24,100,125b,141,143,296 up serum Mitchell, 2008 [35]
141,200b, 200c up prostate cells Mitchell, 2008 [35]
221 up PCa cells Mercatelli, 2008 [42]
221 up tumor Spahn, 2009 [91]
9*,15a,16,145,221,222,331,551a up PCa cells Wang, 2009 [90]
128 up PCa cells Khan, 2010 [88]
let-7a,let-7c,let-7f,15b,20a,21,25,26b,30b,106a, 106b, 126*,148a,200c,218,375, up tumor Szczyrba, 2010 [61]
25,93,106b up tumor Poliseno, 2010 [61]
96,182,182*,183 up tumor Schaefer, 2010 [81]
141 up plasma Gonzales, 2011 [133]
182 up Prostate cells Mihelich, 2011 [98]
100,145,191,let7c up tumor Leite, 2011 [138]
9*,141,200b,375,516a-3p up serum Brase, 2011 [115]
21 up plasma Yaman Agaoglu, 2011 [54]
34c up PCa cells Hao, 2011 [95]
20a,21,221 up plasma Shen, 2012 [56]
107,141,301a,326,432,484,574-3p,625*,2110 up plasma Bryant, 2012 [117]
21 up tumor Li, 2012 [55]
let-7b,7,9*,17,19b,20a,21,25,30d,32,92a-1*,93,95,96,106a*,106b, 106b*,130b,
142-3p,141*, 148a, 153,182,182*,183,183*,200b*, 200c*, 210,301b,363,375,
425,512-3p,583,615-3p,663,801,
up tumor Martens-Uzunova, 2012 [48]
let-7a,20a,21,106a,106b,375, up tumor Wach, 2012 [10]
96,124,141,302b,375,378*,489,520d-5p,548a-3p,548c-3p, 875-5p,892b, up serum Nguyen, 2013 [116]
96-5p,183-3p,183-5p up tumor Larne, 2013 [108]
10b,15a,15b,16,18a,18b,20b,25,30c,32,34a,34c-5p, 92a, 122, 124,125a-5p,
125b,128a,133b, 134, 135b,146b-5p,148b,181a,181b,181c,184,193a-5p,
193b,206,214, 215,301a,372
up tumor Walter, 2013 [110]
19a,188-5p,574-5p,663,939,1224-5p,1225-5p,1249,1915,K12-3,UL70-3p, up tumor He, 2013 [134]
21 up tumor Amankwah, 2013 [102]
32,106b-25,375 up tumor Hudson, 2013 [53]
96-5p,182-5p,183-5p, up tumor Tsuchiyama, 2013 [106]
141,200a,200c,210,375 up serum Cheng, 2013 [120]
19a,19b,20a,20b,26a,26b,29c,106a,125a,125b,135a, 141, 148a,151–5p,174b,
193a, 196b, 331-3p,365, 374a, 374b, 1274b,
up tumor Lichner, 2013 [135]
19b up tumor Wang, 2014 [124]
182,SNORD78,U17b,U78_s,U78_x up tumor Casanova-Salas 2014 [111]
17*,200b*,210,297,375,501-3p,551b,562 up serum Haldrup, 2014 [113]
345,519c-5p up serum Wang, 2014 [124]
93,106b-25 up PCa cells Liang, 2014 [61]
Let-7a,103,107,130b,106a,26b,451,223,93,24,30c,874,100, 146a up serum Mihelich, 2015 [125]
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Pesta et al. [93] evaluated the expression of four miR-
NAs, miR- let-7a, −15a, −16, and 20a in 53 prostate
tumor and 85 benign prostatic hyperplasia (BPH) tissues
to investigate whether miRNA expression is related to
clinic-pathological features of PCa. They observed a
difference in expression for miR-20a in patients with a
Gleason score of 7–10 compared with patients with a
low Gleason score of less than 6, suggesting an onco-
genic role for miR-20a in PCa development [93].
Although the previous study demonstrated the potential
of miR-20a to distinguish between more and less aggres-
sive PCa disease, the use of BPH tissue is not the most
appropriate control relative to normal tissue and poten-
tially impede the identification of unique miRNAs in
PCa. On the other hand, Taylor et al. [94] reported that,
the copy-number alterations in prostate tumors
modestly revealed distinct subgroups with substantial
differences in time to biochemical recurrence while
Table 2 Summary of miRNA expression studies on prostate tumor/serum samples (Continued)
let-7a-5p,let-7d-3p,let-7d-5p,7-5p,7b-5p,20a-5p,21-3p,25-3p, 29b-2-5p,30d-3p,
92a-3p, 92b-3p, 93-3p,96-5p,103a-3p,107, 130b-3p, 182-5p,183-5p,191-5p,
196b-5p,200b-3p, 200b-5p, 200c-3p 329, 331-3p,339-3p,342-5p,375,421,
423-3p,423-5p, 425-5p, 484, 615-3p,663a,663b,664a-3p, 1248,1260a
up tumor Kristensen, 2016 [112]
Let-7a,let-7b,let-7c,let-7d,let-7 g,16,23a,23b,26a,92,99a,103,125a,125b,143,
145,195,199a, 199a*,221,222,497
down tumor Porkka, 2007 [87]
let-7b,1-2,34a,145,7-1/2,126,128a,133a-1,145,205,218-2,220,221,329,340,345,
410, 487,490,494,499,520 h
down tumor Ambs, 2008 [40]
let-7b-g, 26a-b,29a-c,30a-e,99a-b,125a-b,145, 200a-b down tumor Ozen, 2008 [79]
22,24,27a,27b,29a,30e,101,125a-5p,125b,143, 145, 152, 199a-5p,221,223,
320,424,
down tumor Szczyrba, 2010 [61]
16,31,125b,145,149,181b,184,205,221,222 down tumor Schaefer, 2010 [81]
34c down tumor Hagman, 2010 [92]
34c down PCa cells Hao, 2011 [95]
30c,100,223,346 down Prostate cells Mihelich, 2011 [98]
141 down plasma Yaman Agaoglu, 2011 [54]
143,145,221 down tumor Wach, 2012 [10]
1,15a,16-1,133a down tumor Kojima, 2012 [52]
1,10b,27b,29a,29b,34b,126,126*,130a,133a,133b,139-5p,142-3p,142-5p,143,
143*,145,145*, 146a,149,150,155,181b,193b,193b*,204,205,221,221*,222,223,
224,328,338-3p, 342-5p, 361-3p 378,378*,455-3p,455-5p,483-3p,485-3p,551b
down tumor Martens-Uzunova, 2012 [48]
181a-2* down plasma Bryant, 2012 [117]
31-5p,34c-5p,205-5p,221-3p,222-3p down tumor Tsuchiyama, 2013 [106]
101 down tumor Hudson, 2013 [49]
221,222 down tumor Amankwah, 2013 [102]
23b,26b,30c,155,181d,193a-5p,200b-5p,205,221,221-5p,222,224,335,374a,
374b, 455-3p,505
down tumor He, 2013 [134]
145-5p,205-5p,221-5p,409-5p down tumor Larne, 2013 [108]
224 down tumor Mavridis, 2013 [109]
222 down serum Cheng, 2013 [120]
409-3p,623, down serum Nguyen, 2013 [116]
19a,19b down serum Wang, 2014 [124]
34a*,34c-3p,187,221*,221,224, down tumor Casanova-Salas 2014 [111]
1,133b down tumor Karatas, 2014 [55]
1 down Prostate cells Chang, 2015 [46]
15a-5p,16-5p,19b-3p,22-3p,23a-3p,23b-3p,24-3p,26a-5p, 27a-3p, 27b-3p,
29a-3p, 29b-3p,30a-3p,30a-5p,30c-5p,30e-3p, 30e-5p, 33a-5p,34a-5p,99a-3p,
99a-5p,101-3p, 125b-2-3p, 125b-5p, 127-3p,130a-3p,132-3p,136-5p,143-3p,
149-5p, 152, 154-5p,155-5p, 181a-5p,181b-5p,195-5p, 199a-3p,199a-5p, 199b-5p,
205-5p, 214-5p,218-5p,221-3p,222-3p, 223-3p,335-5p,338-3p,362-3p,
363-3p376a-3p,376c-3p,424-5p, 451a,455-3p, 455-5p,497-5p,502-3p,660-5p
down tumor Kristensen, 2016 [112]
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unsupervised hierarchical clustering of mRNA and
miRNA data failed to identify robust clusters of patients
with significant differences in prognosis [94].
Szczyrba et al. [61] found 16 miRNAs upregulated by
at least 1.5-fold and 17 miRNAs downregulated by at
least 1.5-fold in snap frozen prostate tumor tissue.
Strong upregulation was found for miR-148a, −200c,
−375, and the miR-143, −145 and −223 were downregu-
lated [61]. In another study by Hao et al. [95], miR-21,
and miR-141 were upregulated at least 2-fold, while
miR-10, −16, −34c, and -125b, were downregulated in
formalin fixed paraffin embedded (FFPE) tumor tissues
as compared with BPH specimens [95]. The positive pre-
dictive value was enhanced from 40 to 87.5% when the
PSA variable was added with expression variable of miR-
21 and miR-141. After analysis of tumor samples from
Caucasians and African-Americans, miR-182 level
tended to be higher in PCa tissues and miR-30c, −100,
−223, and −346 were expressed at lower levels in PCa
tissue in Caucasians.
Therefore, miR-21 may indicate a potential role of car-
cinogenesis in prostate tissue [57]. In addition, multiple
studies reported that miR-21 is an oncogene in prostate
cancer and over-expression may be related to the devel-
opment of castration-resistance PCa [57–60, 96]. In
addition, Bonci et al. [97] recently reported over-
expression in PCa metastasis.
A RNA microarray profiling analysis of a patient co-
hort with organ-confined prostate tumors indicated the
overexpression of miR-96, −182, and −183 with at least
2-fold in laser captured micro-dissected (LCM) PCa tis-
sue compared with normal adjacent prostate tissue [98].
Moltzahn et al. [99] identified miRNA signatures which
can distinguish healthy controls from patients and
correlate with a prognosis. Cluster and ROC analyses
indicated the diagnostic potential and the ability to
further separate PCa patients according to their risk
of recurrence by their miRNA signatures [99]. Zhang
et al. [100] assessed a potential role of serum miR-21
in the progression of PCa with 56 patients, including
20 localized PCa, 20 with androgen-dependent PCa
(ADPC), 10 with hormone-refractory PCa (HRPC),
and 6 with BPH. Significantly higher levels of miR-21
were detected in patients with ADPC and HRPC,
especially in those resistant to docetaxel-based
chemotherapy. These findings suggest miR-21 may be
a biomarker at the transition to hormone refractory
disease and a potential indicator for response to treat-
ment in PCa patients [100].
Martens-Uzunova et al. [48] analyzed the expression
of miRNAs in 102 prostate tumor tissues, adjacent
normal tissues, lymph and trans-urethral resection from
normal and PCa patients. Regarding the miRNAs, the
authors analyzed 80 miRNA species, where 22 were
identified with significant differences between the two
groups with or without PCa that can serve as a diagnosis
markers. The authors also identified a miR profile con-
sist of 25 miRNAs, which 12 overexpressed and 13
under-expressed in prostate tumor tissues with poor
outcome. This 25 miRNA profile is very accurate to pre-
dict a recurrence (AUC = 0.991, p < 0.0001 Kaplan-Meier
analysis). They also observed that the overall expression
of miRNA was lower in PCa malignant lymphoma com-
pared to the PCa prostate tissues. 19 miRNAs have been
upregulated in metastatic lymph node while 69 miRNAs,
including miR-1, −133a, −133b, −143, −143*, −145,
−145*, −204, −221 and −222, have been downregulated
in comparison to PCa tissue [48].
Li et al. [55] confirmed the miR-21 expression in 169
PCa tissue samples was significantly associated with clin-
ical variables, such as stage, lymph node involvement,
capsular invasion, organ confined disease, Gleason score,
BCR and patient follow-up. The relationship between
miR-21 as BCR persisted even after adjusting for stand-
ard clinico-pathological parameters (i.e., PSA, patient
age, Gleason score, surgical margin, lymph node metas-
tasis, capsular invasion, and pathological stage) [55].
Avgeris et al. [101] evaluated the clinical utility of
miR-145 using 137 prostate tumor tissues and 64 benign
samples. They found that the reduction of miR-145 ex-
pression in PCa was correlated with Gleason score, clin-
ical stage, tumor size and PSA level and follow-up PSA
levels. Further, the reduction of miR-145 expression was
significantly associated with increased risk for biochem-
ical recurrence and shorter disease-free survival (DFS)
among PCa patients. This relationship remained signifi-
cant after adjusting for Gleason score, clinical stage, PSA
and age at diagnosis [101]. We [102], reported a signifi-
cantly increased risk for recurrence (p < 0.0001) in
patients with decreased expression of miR-21, but not
for miR-221 (p = 0.57) or miR-222 (p = 0.24). An in-
creased risk of recurrence was more prominent in obese
(p = 0.031) than non-obese patients. After adjustment for
stage and Gleason score, the results showed miR-21 ex-
pression was independently linked to disease recurrence
among obese patients [102].
Barnabas et al. [103] observed a copy number gain of
miR-151 gene at 8q24 in PCa tissues from African-
American men who developed BCR after radical prosta-
tectomy. These data suggested a copy number gain of
miR-151 gene in primary tumor that may indicate the
presence of metastatic disease [103]. Leite et al. [104]
observed a 2.7-3.4 fold higher likelihood of BCR when
miR-100, −145, −191, and let-7c were over-expressed.
However, only miR-100 showed a significant association
independently with BCR in multi-variable analysis [104].
Srivastava et al. [105] evaluated expression of 8 miR-
NAs in 40 paired prostate tissues. miR-205, miR-214,
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miR-221 and miR-99b were significantly downregulated
in PCa tumor tissue. These miRNA profiles can discrim-
inate PCa patients from healthy individuals successfully
[105]. Tsuchiyama et al. [106] tested whether levels of
miRNAs were correlated with aggressiveness. Expression
of miR-315p, −34c-5p, and −205-5p was significantly de-
creased compared to those in normal tissues regardless
of Gleason pattern (p < 0.05). Meanwhile, in the same
patients with high grade PCa, expression of miR-31-5p
−182-5p, and −205-5p in tumor tissues was higher than
ones obtained from intermediate Gleason tumor (p <
0.05) [106]. Using prostate tissues from 23 PCa and 25
BPH patients from Turkey, 4 candidate miRNAs were
evaluated (i.e., miR-133b, −203, −221, and −361-3p).
miR-361-3p was significantly lower in tumor tissues
from PCa than BPH patients (p = 0.004). Both miR-133b
and miR-221 were downregulated in PCa compared to
BPH (p < 0.01 and 0.03, respectively). The levels of miR-
203 were found to be significantly upregulated in PCa
samples (p = 0.0002). The AUC values of all miRNAs,
miR-133b, miR-203, miR-221, and miR-361-3p were
0.73, 0.81, 0.71, and 0.74, respectively [107].
Larne et al. [108] developed a formula which can pre-
dict early stage of PCa with aggressive progression char-
acteristics. Using differentially expressed miRNAs in
PCa tissue samples, the authors developed a miRNA sig-
nature, consisting of four miRNAs [(miR-96-5p x miR-
183-5p)/(miR-145-5p x miR221-5p)], denoted as the
miRNA index quote (miQ). The miQ provided an excel-
lent diagnostic discrimination. The median of miQ is 17
times higher in the PCa group compared to the non-
PCa group (p < 0.0001). Further, miQ level is also associ-
ated with grades (p = 0.0067), PSA levels (p < 0.0001),
metastasis (p < 0.0001) and survival (p = 0.0014). More
importantly, miQ distinguishes aggressive tumors from
non-aggressive PCa (p < 0.0001) with an AUC of 0.90
(95% CI: 0.77–0.97) [108].
Mavridis et al. [109] reported that miR-224 could dis-
tinguish PCa patients from BPH patients with an AUC
of 0.67 (p = 0.001) in tissue samples. miR-224 expression
inversely correlated with aggressiveness (p = 0.017), thus
Gleason score, advanced disease stage, PSA, risk of re-
lapse and positively with progression-free survival [109].
Walter et al. [110] found upregulation of miR-143 and
miR-146b and loss of 18 miRNAs (e.g. miR-34c, −29b,
−212 and -10b) in the PCa tumors relative to normal
epithelium and/or stroma (p < 0.001). In addition, upreg-
ulation of 11 miRNAs and downregulation of 7 miRNAs
were found in the tumors with high Gleason score (≥8)
when compared with ones with Gleason score 6 [110].
Casanova-Salas et al. [111] found the expression miR-
182 was increased in PCa tissue samples and decreased
6 miRNAs, miR-34a*, −34c-3p, −187, −221*, −221 and.
224. Further miR-182 and miR-187 were also
differentially expressed according to clinical variables,
such as Gleason score, stage, status of TMPRSS2-ERG
and progression [111].
In one of the largest miRNA profiling studies pub-
lished for PCa, Kristensen et al. [112] analyzed the
expression of 752 miRNAs in a training set of 13 non-
malignant and 134 PCa tissue samples. Subsequently, a
total of 93 miRNAs with diagnostic/prognostic potential
were selected for further validation in two similar-sized
independent patient cohorts. The authors identified sev-
eral novel deregulated miRNAs in PCa as compared to
nonmalignant prostate tissue samples as well as between
more/less aggressive PCa subgroups, as defined by
clinic-pathological parameters. Most notably, the authors
also identified a novel 3-miRNA prognostic signature
(miR-185-5p +miR-221-3p +miR-326) predicted time to
biochemical recurrence after radical prostatectomy inde-
pendently of routine clinical variables in a training co-
hort as well as in two independent validation cohorts.
This is the first report to demonstrate independent prog-
nostic value for a miRNA signature in three independent
PCa patient cohorts, supporting the potential clinical
relevance of this signature [112].
Diagnosis/progression of prostate cancer based on serum
Some studies have examined the differential expression
of miRNAs in serum or plasma in an attempt to develop
a blood based diagnosis, detection of progression and re-
currence of PCa. Mitchell et al. [35] showed that serum
levels of miR-141 can distinguish PCa patients from
healthy controls, supporting the potential role of this
miRNA as a diagnostic marker for PCa. The up-
regulation of miR-141 in PCa patients was confirmed in
later studies [54, 95, 113–117]. Mahn et al. [118] found
circulating oncogenic miRNAs (i.e., miR-26a, −32, −195
and let-7i), particularly miR-26a have a sensitivity of 89%
and specificity of 56% (area under the curve: AUC =
0.70) for diagnosis. The diagnostic accuracy increased
when these four miRNAs were analyzed in combin-
ation (sensitivity: 78.4%, specificity: 66.7%, AUC =
076). Increased levels of miR-16, −26a, and −195 were
inversely associated with surgical margin positivity.
miR-195 and -let7i were also inversely associated with
Gleason score. They found a significant reduction of
miR-16, −26a, and −195 levels after radical prostatec-
tomy. miR-32 was found to be down-regulated in PCa
tissue (p = 0.02) [118].
Chen et al. [119] found that a panel of five serum miR-
NAs (let-7c, let-7e, miR-30c, −622 and −1285) were sig-
nificantly different in PCa patients as compared to
healthy controls in both identification and validation
cohorts. All 5 miRNAs could distinguish PCa from
healthy controls individually. The respective sensitivity
and specificity values were: let-7c, 68.5 and 70%; let-7e,
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77.8 and 75%; miR-30c, 79.6 and 68.8%; miR- 622, 90
and 63.0%; miR-1285, 61.3 and 57.4% [119]. Wach et
al. [10] reported on the detection of miR-145 in
endothelial cells of blood vessels but not stromal
cells. Based upon the ratio of miRNA expression, they
concluded that miR-145 may be the best negative pre-
dictive biomarker suitable for diagnostic or prognostic
purposes in PCa [10].
Selth et al. [114] used a mouse model of PCa as a tool
to discover serum miRNAs that could be used in a clin-
ical setting. Among 45 miRNAs identified, four miRNAs
(miR-141, −298, −346, and −375) were significantly ele-
vated in metastatic PCa samples as compared to those in
healthy controls (all p < 0.05). miR-141 and miR-375
were associated with biochemical recurrence (BCR)
[114]. Cheng et al. [120] identified five serum miR-
NAs (miR-141, −200a, −200c, −210, and −375) associ-
ated with metastatic castration resistant PCa in both
screening and validation cohorts. In the screening co-
hort, serum levels of five miRNAs were significantly
increased in PCa cases as compared with controls
(miR-141: p < 0.0001, AUC = 0.90; miR-200a: p = 0.007,
AUC = 0.70; miR-200c: p = 0.017, AUC = 0.72; miR-
210: p = 0.02, AUC = 0.68; and miR-375: p = 0.009,
AUC = 0.77), while the respective p-values of these
five miRNAs were 0.001, 0.073, 0.055, 0.022, and
0.021 in a validation cohort [120].
Haldrup et al. [113] performed genome-wide miRNA
profiling of serum samples from 13 BPH control and 31
PCa patients. The dysregulation of miR-141 and −375,
two of the most well-documented candidate miRNA
markers for PCa, was confirmed. Further, they developed
three novel and highly specific miRNA panels (miR-
562/-210/-501-3p/-375/-551b) able to identify 84% of all
PCa patients, 80% of patients with disseminated PCa
(let-7a*/miR-210/-562/-616), and 75% of disseminated
PCa patients when compared to localized PC patients
(miR-375/-708/-1203/-200a) [113]. miR-141 levels were
significantly increased in patients with a higher Gleason
score (p = 0.05) although the levels of miR-26a-1 and
−141 in 170 pre-biopsy serum samples were similar in
patients with positive and negative biopsies (p = 0.72,
AUC = 0.52 and p = 0.84, AUC = 0.49, respectively) [121].
The expression levels of 4 miRNAs in plasma from 59
PCa patients with different clinic-pathological character-
istics and two groups of controls, 16 BPH samples and
11 young asymptomatic men (YAM) were analyzed to
evaluate their diagnostic and prognostic value in com-
parison to PSA. miR-375 was significantly downregu-
lated in 83.5% of patients compared to BPH controls
and showed stronger diagnostic accuracy (AUC = 0.81,
95% CI: 0.70–0.92, p = 0.00016) compared with PSA
(AUC = 0.71, 95% CI: 0.56–0.86, p = 0.013). Sensitivity of
86.8% and specificity of 81.8% were reached when all
biomarkers were combined (AUC = 0.88) and YAM were
used as calibrators [122].
In a study of 51 PCa patients and 20 healthy controls
in Turkey, Yaman Agaoglu et al. [54] investigated the
levels of miRs-21, −141, and −221 in plasma of patients
and healthy controls. They found miR-21 and miR-221
levels were significantly higher in prostate patients than
controls (p < 0.001, ROC-AUC = 88% and p < 0.001,
AUC = 83%; respectively), but not for miR-141 (p = 0.20).
miR-141, however, was found to be significantly higher
in local advanced patients in comparison with those
diagnosed with local outcome (p < 0.001, AUC = 76%)
[54]. Brase et al. [115] observed enhanced expression of
miR-375 and miR-141 in prostate tumor tissue com-
pared to normal tissue and both miRNAs were upregu-
lated in the sera of patients with metastatic disease
compared to those with localized disease and correlated
with high Gleason score or lymph-node positive status.
These findings show miR-375 and miR-141 detection in
serum may be associated with advanced disease [115].
Nguyen et al. [116] demonstrated over-expression
miR-375, −378, and −141 were significantly in serum
collected from castration resistant PCa patients com-
pared to those with localized disease, while miR-409-3p
was significantly under-expressed. In prostate tumor
tissues, the expression of miR-375 and miR-141 were
significantly higher than those in normal prostate tis-
sue [116]. Relative to normal tissue, miR-205 (down-
regulated in mCRPC) was indicated by Watahiki et al.
[123] to be associated with a lower Gleason score and
a lower probability of both BCR and clinically evident
metastatic events after prostatectomy. To the
contrary, miR-141, 151-3p, 152 and 423-3p are in-
versely associated with prognosis and/or Gleason
score. miR-141 and −152 may identify individuals
with a high probability of recurrence after surgical
treatment. miR-423-3p and miR-205 were suggested
as novel prognostic factors due to their correlation
with several clinical parameters [123].
Wang et al. [124] investigated whether pre-surgical
serum levels of miRNAs can identify PCa patients. miR-
19a and miR-19b displayed higher expression in the case
group compared to controls, consistent with higher
serum levels in cases. Conversely, miR-345 and -519c-5p
had significantly lower expression among PCa patient.
These results were consistent with lower levels in the
patients’ serum samples. Logistic regression models for
predicting case/control status showed all four miRNAs
as highly significant predictors of outcome status even
when controlling for age, PSA, clinical stage, and degree
of biopsy involvement. In the validation cohort, expres-
sion data of 4 miRNAs were consistent with data from
the discovery cohort. Models consisting of a combin-
ation either miR-19a or -19b together with miR-345 and
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- 519c-5p showed an AUC of 0.94, reaching high signifi-
cance (p = 0.02 and p = 0.017 respectively) [124].
Shen et al. [56] also found miR-20a, −21 and −145
levels were significantly associated with PCa but not dis-
ease aggressiveness. The combination of these three
miRNAs was a significant predictor and distinguished
high risk PCa patients [56]. Martens-Uzunova et al. [48]
evaluated some miRNAs significantly different in
lymphocytes that could be used in the evaluation of pro-
gression of PCa, although some demonstrated an upreg-
ulation 2 fold-change or more between normal and PCa
tissue (miR- 95, 96, 32, 153,182, 182*, 183) were and
others (miR-133a, 133b, 221, 221*, 222, 224, 338-3p,
378*, 455-5p) were downregulation, especially miR-205
showed 6.3 fold downregulation [48]. Karatas et al.,
studying tissue samples from patients with recurrent and
non-recurrent PCa, confirmed a negative uptake of miR-
1 and miR-133b, miR-145* in recurrent Pca [51].
Mihelich et al. [125] developed the equation, miR Risk
Score based on 7 miRNAs, miR, let-7a, −26b, −106a,
−107, −130b, −223, and −451 in plasma samples. This
scoring system showed to be highly predictive of low-
grade PCa. The AUC for low-grade PCa was 0.69 across
the range of miR risk scores [125]. Bryant et al. [117] re-
ported 12 miRNAs were differentially expressed in PCa
patients plasma compared with controls. Among the 12
miRNAs, 11 were significantly correlated with metasta-
ses. The association of two miRNAs, miR-141 and miR-
375 with metastatic PCa was confirmed in a separate co-
hort. An analysis of urine samples indicated miR-107
and miR-574-3p were significantly associated with PCa
risk [117].
Diagnosis/progression of prostate cancer based on urine
and ejaculation
Srivastava et al. evaluated expression of 8 miRNAs in
urine and tissue samples. miR-205, and miR-214 were
significantly downregulated in PCa patients in both
tissue and urine specimens. This miRNA profile can
discriminate PCa patients from healthy individuals with
89% sensitivity and 80% specificity [105]. Haj-Ahmad et
al. [126] performed miRNA expression profiling with
urine samples obtained from 8 PCa patients, 12 BPH
patients and 10 healthy males using whole genome
expression analysis. Differential expression of two indi-
vidual miRNAs between healthy males and BPH patients
was detected and found to possibly target genes related
to PCa development and progression among 894 miR-
NAs assayed. The authors found the sensitivity and spe-
cificity of miR-1825 for detecting PCa among BPH
individuals were 60 and 69%, respectively. Further, the
sensitivity and specificity for miR-1825 and −484 using
tandem deregulation at the same time were 45 and 75%,
respectively [126]. Another urine study suggested miR-
483-5p was significantly associated with PCa based on
samples from 71 PCa patients and 18 controls (p = 0.01;
AUC = 0.69) [127].
Roberts et al. [128] evaluated the diagnostic per-
formance of ejaculated-derived PCA3, Hepsin, and
miRNAs (miR-125b, −200b, −200c, and −375) in 61
PCa patients. In stratified analysis, miR-200c (AUC =
0.79) and miR-375 (AUC = 0.76) demonstrated as the
best single marker performance, while a combination
of serum PSA, miR-200c and miR-125b further im-
proved a prediction capacity for PCa status as com-
pared to PSA alone determined by biopsy (AUC =
0.87 vs. 0.67; p < 0.05), and prostatectomy pathology
(AUC = 0.81 vs. 0.70). For PCa status by biopsy, the
specificity enhanced from 11% for PSA only to 67%
for a combination of PSA, miR-200c, and miR-125b,
with 90% specificity [128].
miRNA as predictors of therapeutic response for prostate
cancer
miRNAs affect the expression of multiple genes in
disease pathways and therefore represent interesting
drug targets. Different experimental approaches used to
validate the function of miRNAs can be potentially
developed for miRNA-based therapies. For example,
over-expressed oncogenic miRNAs can efficiently be
inhibited using modified antisense oligonucleotides and
this strategy was positively evaluated in animal models
[129–131]. Expression of down-regulated tumor sup-
pressor miRNA can be restored using synthetic precur-
sor double stranded miRNA molecules or miRNA
expression vectors delivered through lentiviral systems
[67, 86]. miRNAs can also be exploited to increase the
sensitivity of tumor cells to conventional anticancer
agents [86]. For example, identification of miRNAs
involved in the transition from androgen-independent to
androgen-dependent state will aid in the modulation of
the androgen-independent phenotype with the aim of
increasing the responsiveness of advanced PCa to
anticancer therapies. Some studies have currently
demonstrated miRNAs are differentially expressed in
androgen-independent compared to androgen-dependent
PCa cell lines [65, 66, 73, 132].
With Low-Density Arrays (TLDA) to screen differen-
tially expressed serum miRNAs, Cheng et al. [120] found
that serum level of miR-210 were correlated with PSA
level change per day during treatment (p = 0.029). Fur-
thermore, expression of miR-210 was significantly lower
in non-aggressive disease patients, as compared to those
with recurrence (p = 0.001). The authors suggest that a
subset of mCRPC patients may have a higher hypoxia
response signaling, leading to increased miR-210 and
therapy resistance. These data suggested miR-210 levels
could be used to identify a distinct, subset of mCRPC
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patients with tumor-associated hypoxia. Gonzales et al.
[133] studied in 21 PCa patients in a longitudinal man-
ner with multiple blood draws. They determined the
levels of miR-141 in PCa patients and compared it to
the levels of three other conventional PCa biomarkers:
PSA, lactate dehydrogenase (LDH) and circulating
tumor cells (CTC). Then they found that miR-141 level
changes were similar with changes observed by PSA,
LDH and CTC and to the clinical assessments of the
patients, suggests miR-141 can be used as a marker for
therapeutic response in PCa patients. He et al. [134]
reported that 28 miRNAs were differentially expressed
between PCa tumor and adjacent benign tissues. The
authors compared the miRNA expression profiles to
non-Chinese populations and found that miR-23b, −220,
−221, −222, and −205 may be common targets for treat-
ments in all populations. This study also identified 15
specific miRNAs in Chinese patients. miR-374b and
miR-19a showed significant correlations with clinical-
pathological features in Chinese patients [134].
Lichnew et al. [135] confirmed results for 2 miRNAs
were downregulation of miR-331-3p (p = 0.009) in the
low-risk BCR group and miR-152 in the high-risk group
(p = 0.012). To further confirm their results, using a sec-
ond independent set of PCa cases, they observed similar
results, as expected. The prediction model correctly clas-
sified high-risk individuals (33/35, 94.3%) and low-risk
individuals (6/29, 20.7%) [135]. Someya et al. [136] in-
vestigated an association between miRNA expression
and radio-sensitivity of PCa patients. They observed
different miRNA expression among PCa patients with
different radiation treatments. Three miRNAs (miR-99a,
−147 and −508) in non-irradiated peripheral blood
lymphocytes (PBLs) and one miRNA in irradiated PBLs
(miR-199b), and significant induction of 11 miRNAs by
irradiation (miR- 28, −185, −221, −340, −376c, −422a,
−486, −491, −542, −652 and −660) were found. The
authors concluded a combination of low ATP-
dependent DNA helicase II (Ku80/XRCC5) expression
and highly-induced miR-99a expression could be a
promising marker for predicting radio-sensitivity after
radiotherapy [136].
Conclusions
miRNAs regulate gene expression post-transcriptionally
by both destabilizing mRNA and inhibiting their transla-
tion. Post-transcriptional regulation guarantees rapid
and reversible changes in protein synthesis without alter-
ing transcription. Further, miRNAs can simultaneously
modulate several cancer-relevant gene networks, because
of their ability to bind to several targets. These attributes
make miRNAs attractive candidates relevant as one-hit
multi-target (polypharmacological) therapeutic agents
against PCa and cancer in general. Further, miRNAs
represent a potential source of PCa diagnostic bio-
markers. The stability of miRNA in serum and plasma
and previous work showing differential expression of
serum miRNA in normal and tumor tissue suggest the
potential of miRNA as blood-based biomarkers for PCa
diagnosis.
However, detailed knowledge of their expression, regu-
lation, target genes and mechanism of action is required
to achieve this goal. Moreover, it is critical to establish
standard protocols for miRNA normalization and collec-
tion of tissue biospecimens. Some studies analyze
miRNA expression in laser micro-dissected tumor tissue
to procure tumor tissue with high purity [40, 98, 105,
106]. Unfortunately, other studies continue to analyze
miRNA expression in snap frozen or FFPE tissue as
observed in this review [61, 95, 101]. RNA endogenous
controls (e.g., RNU44, RNU6B) can vary from study to
study. The analysis of miRNA expression in non-micro-
dissected tumor tissue and use of various miRNA
endogenous controls, may skew miRNA expression pro-
files in PCa. For biological fluids (i.e., serum, plasma,
urine), there is no designated endogenous control to
normalization miRNA expression in cancer. However,
some studies utilize stable synthetic Caenorhabditis ele-
gans (i.e., Cel-39, −54, −238) as spike-in internal controls
to normalized miRNA expression in serum [35, 115]. It
is well known that African American men are 2.5 times
more likely to die from PCa relative to Caucasian men
[1]. In this review, majority of the miRNA profiling stud-
ies utilized pre-dominantly Caucasian populations.
Given this apparent racial disparity in PCa, more
miRNA profiling studies in diverse populations are
needed to identify ethnic-specific miRNAs that may
possibly play a role in aggressive disease among African
American men. Ultimately, miRNA profiling in tumor
tissue and biological fluids collected from more diverse
populations using more standardized miRNA normalization
protocols may lead to the identification of more key
miRNAs and elucidate the role of miRNAs in PCa
disease prevalence in certain populations.
Further studies in in vivo knockout or knock-in
models should be helpful in understanding the pathways
affected by miRNAs. Further, gene expression and prote-
omic analysis associated with loss- and gain-of-function
studies in different model systems might contribute to a
better understanding of the cellular networks affected by
miRNA in the development and progression of cancer
[5]. Additional investigation is also warranted to ascer-
tain whether dysregulation of miRNA expression is
causative rather than a consequence of cancer.
In summary, expression profiling studies provide evi-
dence for the role of miRNAs in PCa diagnosis and
prognosis. However, limited overlap exists between these
studies and an extremely limited number of PCa-related
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miRNAs are currently known. Present promising candi-
dates are miR-1, −21, 106b, 141, miR-145, miR-205,
miR-221, and miR-375, which are the most frequently
studied and seem to be the most promising for diagnosis
and prognosis for prostate cancer.
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